Clinical Trial Update: Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation [NA]

View source ↗

Summary

A completed clinical trial assessing safety and effectiveness of the TactiCath SE catheter for ablation in patients with drug-refractory, symptomatic persistent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Atrial Fibrillation

Drugs mentioned

• TactiCath SE Contact Force Sensor Enabled Catheter

Snippet

Sponsor: Abbott Medical Devices | Conditions: Persistent Atrial Fibrillation | NA | Status: COMPLETED | Results posted: 2022-04-27